Danaher Corporation is a science and technology company organized into three segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment, established through the acquisition of Pall in 2015 and expanded by the acquisition of Cytiva in 2020, provides bioprocessing technologies, consumables, and services for the development and manufacture of biological medicines, including monoclonal antibodies, cell and gene therapies, and nucleic acid-based therapies. The Life Sciences segment, built through acquisitions such as Leica Microsystems, AB Sciex, Molecular Devices, Beckman Coulter, Phenomenex, IDT, Aldevron, and Abcam, offers instruments, consumables, and software for studying DNA, RNA, proteins, and cells to support drug discovery, development, and manufacturing. The company serves pharmaceutical and biopharmaceutical companies, contract manufacturing organizations, academic and translational research institutions, and clinical care providers. Danaher sells its products primarily through direct sales and independent distributors in North America, Europe, Asia, and high-growth markets. The company was founded in 1984 by Steven M. Rales and Mitchell P. Rales and operates under the Danaher Business System framework.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage danaher.com
Sector Healthcare IR page investors.danaher.com
Tags
bioprocessing, cell and gene therapy, molecular diagnostics, life sciences instruments, chromatography resins, filtration technologies, liquid handling systems, centrifugation, genomic medicine, biotherapeutics, recombinant proteins, vaccines, Cytiva, Pall, Leica Microsystems, AB Sciex, Molecular Devices, Beckman Coulter, Phenomenex, IDT, Aldevron, Abcam, Radiometer, Fortive, Veralto, Blue Whale Bio
Press page investors.danaher.com/press-releases

Metrics

Valuation  
Market cap $ 164.001B
Market cap (USD) $ 164.001B
P/E 38.47
PEG —
P/BV 3.06
P/S 6.40
P/OCF 23.91
P/FCF 28.64
Dividend yield <0.01%
Turnover / mcap —
Returns  
ROE 7.1%
ROI 5.1%
ROIC 5.6%
Profit margin 14.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -20.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 49.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 59
Quality score -15.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 24.568B 23.875B 23.89B 31.471B 29.453B 22.284B 17.911B 19.893B 18.33B 16.882B 20.563B 19.914B 19.118B 18.26B 16.091B 13.203B 11.185B 12.697B 11.026B 9.596B 7.985B 6.889B 5.294B 4.577B 3.782B 3.778B
Net profit 3.614B 3.899B 4.764B 7.209B 6.433B 3.646B 3.008B 2.651B 2.492B 2.554B 3.357B 2.598B 2.695B 2.392B 2.172B 1.793B 1.152B 1.318B 1.37B 1.122B 897.8M 746M 536.834M 290.391M 297.665M 324.213M
Free cash flow 5.26B 5.296B 5.781B 7.367B 7.064B 5.417B 3.316B 3.366B 2.858B 2.932B 3.169B 3.161B 3.034B 2.957B 2.292B 1.867B 1.612B 1.665B 1.484B 1.41B — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 228.92 229.55 231.34 265.42 329.01 222.14 153.48 103.12 92.82 77.84 92.88 85.71 77.2 55.9 47.04 47.17 75.21 56.63 83.1 71.15 — — — — — —
Price performance 12m -0 -0.01 -0.13 -0.19 0.48 0.45 0.49 0.11 0.19 -0.16 0.08 0.11 0.38 0.19 -0 -0.37 0.33 -0.32 0.17 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.19B 3.52B 3.49B 3.19B 4.05B 4.63B 4.92B 3.92B 3.54B 3.91B
↳ YoY growth -19.6% +10.5% -0.9% -8.5% +26.7% +14.5% +6.2% -20.3% -9.8% +10.6%
↳ 5y CAGR +0.9% +1.5% +0.2% -2.6% +0.4% +7.8% +6.9% +2.4% +2.1% -0.7%
Borrowings, current (USD) 2.59B 195M 51.8M 212M 11M 8M 591M 1.7B 505M 2M
Borrowings, non-current (USD) 9.67B 10.3B 9.69B 21.5B 21.2B 22.2B 19.1B 16.7B 15.5B 18.4B
Lease liabilities (USD) — — 1.01B 797M 974M 1.1B 1.06B 1.13B 1.14B 1.28B
Cash and deposits (USD) 964M 630M 788M 19.9B 6.04B 2.59B 6B 5.86B 2.08B 4.62B
Intangible assets (USD) 11.8B 11.7B 11.7B 9.75B 21.3B 22.8B 20.3B 20.7B 18.6B 17.8B
Right-of-use assets (USD) — — 971M 764M 942M 1.04B 1B 1.05B 1.08B 1.21B
Net debt (borrowings + leases - cash) (USD) 11.3B 9.89B 8.95B 2.61B 16.1B 20.7B 14.7B 13.7B 15.1B 15.1B
Cash flow detail
Operating cash flow (USD) 3.52B 3.48B 4.02B 3.95B 6.21B 8.36B 8.52B 7.16B 6.69B 6.42B
Purchases of property, plant and equipment (USD) -590M -620M -656M -636M -791M -1.29B -1.15B -1.38B -1.39B -1.16B
Change in receivables (cash effect) (USD) -183M -161M -58.3M -156M -264M -611M -477M 322M 331M -216M
Change in inventories (cash effect) (USD) 9.4M -27.4M -143M -21.9M -123M -502M -486M 185M 147M -58M
Change in payables (cash effect) (USD) 78.1M -54.4M 226M 18.1M 227M 549M 5M -149M 19M 9M
Dividends paid (cash effect) (USD) -400M -378M -433M -527M -615M -742M -818M -821M -768M -878M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -5.98B -3.09B
Interest paid (cash effect) (USD) -212M -130M -140M -129M -331M -452M -347M -392M -370M -331M
Income taxes paid (cash effect) (USD) -767M -689M -673M -847M -1.1B -1.7B -1.8B -1.8B -1.3B -1.2B
Share-based compensation (USD) 130M 139M 151M 159M 187M 218M 336M 306M 288M 298M
Operating cash flow before change in receivables (USD) 3.7B 3.64B 4.08B 4.11B 6.47B 8.97B 9B 6.84B 6.36B 6.63B
Free cash flow (OCF - PPE - intangibles) (USD) 2.93B 2.86B 3.37B 3.32B 5.42B 7.06B 7.37B 5.78B 5.3B 5.26B
Income detail
Research and development expense (USD) 975M 1.13B 1.23B 1.13B 1.35B 1.74B 1.75B 1.5B 1.58B 1.6B
↳ 5y CAGR -0.9% -0.2% -0.3% -3.0% +1.7% +12.3% +9.1% +4.1% +7.1% +3.5%
Total comprehensive income (USD) 1.86B 3.52B 2.01B 2.73B 6.35B 5.77B 5.36B 4.91B 2.43B 6.63B
Comprehensive income to owners (USD) 1.86B 3.52B 2.01B 2.73B 6.35B 5.77B 5.36B 4.91B 2.43B 6.63B
Provision for credit losses (USD) 33M 33M 36M 30M 31M 31M 29M 43M 37M 45M
Credit cost ratio (credit losses / average receivables) (%) 0.9% 1.0% 1.0% 0.9% 0.9% 0.7% 0.6% 1.0% 1.0% 1.2%
Reported Feb 22, 2017 Feb 21, 2018 Apr 18, 2019 Feb 21, 2020 Feb 25, 2021 Feb 23, 2022 Feb 20, 2025 Feb 20, 2025 Feb 20, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Danaher Corporation Investors Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences WASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 9, 2026 at 11:45 a.m. ET and Jefferies Global Healthcare Conference in London, UK on November 17, 2026 at 10:00 a.m. GMT. These events will be simultaneously webcast on www.danaher.com. ABOUT DANAHER Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many of their most complex scientific challenges by accelerating discovery, development and the delivery of life-changing therapies. Powered by the Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and Innovation at the Speed of Life. Explore more at www.danaher.com. SOURCE Danaher Corporation

Innovation at the speed of life Bull 4 Bear 0 Results

Danaher Reports Third Quarter 2026 Results

WASHINGTON D.C., October 21, 2026 -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Key Third Quarter 2026 Results

•Net earnings were $1.2 billion, or $1.71 per diluted common share, up 34.5% year-over-year.

•Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11.

•Revenues increased 8.5% year-over-year to $6.6 billion.

•Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year.

•Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion.

Julie Sawyer Montgomery, President and Chief Executive Officer, stated, “We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets.

WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026. All results in

this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Key Third Quarter 2026 Results

Net earnings were $1.2 billion, or $1.71 per diluted common share, up 34.5% year-over-year.

Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11.

Revenues increased 8.5% year-over-year to $6.6 billion.

Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year.

Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion.

Julie Sawyer Montgomery, President and Chief Executive Officer, stated, "We delivered better-than-expected third quarter revenue, earnings and

cash flow, and are encouraged by the improving trends we saw across our end markets. The continued acceleration in core revenue growth

excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert

improving demand into strong financial performance."

Ms. Sawyer Montgomery continued, "Danaher has built a strong foundation, and the time I've spent with our teams and customers during my

transition into the CEO role has only reinforced my conviction in the opportunities ahead. Looking forward, the opportunity for Danaher is clear: to

become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth,

and helps our customers improve outcomes for patients around the world."

Fourth Quarter and Full Year 2026 Outlook

Danaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted

diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting

principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $0.5 billion for the fourth quarter and $1.9

billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which is estimated to be flat in the fourth

quarter and increase sales by 1.0% in the full year, assuming the currency exchange rates in effect as of September 25, 2026) the additional

elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, future acquisitions,

divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to

predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional

elements could be material to our results computed in accordance with GAAP.

For the fourth quarter 2026, the Company anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0%

range year-over-year. We expect respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of

approximately 3.0%.

For full year 2026, the Company is increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62

versus previous guidance of $8.45 to $8.60.

Conference Call and Webcast Information

Danaher will discuss its third quarter results and financial guidance for the fourth quarter and full year 2026, including as applicable key assumptions

with respect thereto, during its investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be

webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the

webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the

next quarterly earnings call.

The conference call can be accessed by dialing 800-267-6316, within the U.S. or +1 203-518-9783 outside the U.S. a few minutes before 8:00 a.m.

ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ326). A replay of the conference

call will be available shortly after the conclusion of the call and until November 4, 2026. You can access the replay dial-in information on the

"Investors" section of Danaher's website under the subheading "Events & Presentations."

ABOUT DANAHER

Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to

improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many

of their most complex scientific challenges by accelerating discovery, development and the delivery of life-changing therapies. Powered by the

Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and

Innovation at the Speed of Life. Explore more at www.danaher.com.

NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS

In addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures.

Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful

information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other

information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing

details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website

(www.danaher.com).

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the fourth

quarter and full year 2026, the Company's expectations regarding business trends, opportunities, market share gains, sustainable profitable growth

and improved patient outcomes and any other statements regarding events or developments that we believe or anticipate will or may occur in the

future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause

actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and

you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs

and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we incurred to finance the

acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the

financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the

impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests

and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability

to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities

and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of

Masimo Corporation), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or

growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and

expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws

and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the

results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry,

security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment

of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax

laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and

environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national

emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or

software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory

measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations

relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including

commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to

collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to

recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors

(including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in

the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum

provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is

available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2026.

These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does

not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and

developments or otherwise.

This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory

approvals, or are available only in certain markets.

DANAHER CORPORATION AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS

($ and shares in millions, except per share amounts)

(unaudited)

Three-Month Period EndedNine-Month Period Ended

September 25, 2026September 26, 2025September 25, 2026September 26, 2025

Sales$ 6,554$ 6,053$ 18,770$ 17,730

Cost of sales(2,717)(2,530)(7,731)(7,173)

Gross profit3,8373,52311,03910,557

Operating costs:

Selling, general and administrative

expenses(2,159)(1,991)(6,091)(6,209)

Research and development

expenses(433)(378)(1,232)(1,160)

Operating profit1,2451,1543,7163,188

Nonoperating income (expense):

Other income (expense), net(9)(14)(85)(135)

Interest expense(135)(67)(305)(210)

Interest income31311917

Earnings before income taxes1,1321,0763,4452,860

Income taxes75(168)(339)(443)

Net earnings from continuing operations1,2079083,1062,417

Earnings from discontinued operations,

net of income taxes28—28—

Net earnings

$ 1,235$ 908$ 3,134$ 2,417

Net earnings per common share from

continuing operations:

Basic$ 1.71$ 1.28$ 4.40(a)$ 3.38

Diluted$ 1.71$ 1.27$ 4.38(a)$ 3.37

Net earnings per common share from

discontinued operations:

Basic$ 0.04$ —$ 0.04$ —

Diluted$ 0.04$ —$ 0.04$ —

Net earnings per common share:

Basic$ 1.75$ 1.28$ 4.44(a)$ 3.38(a)

Diluted$ 1.75$ 1.27$ 4.42(a)$ 3.37(a)

Average common stock and common

equivalent shares outstanding:

Basic703.8710.7705.7714.5

Diluted706.8713.7708.5717.9

(a)Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.

This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's

website (www.danaher.com).

Prompts

Danaher Corporation (ticker DHR), listed in United States.

Company History

Date Change Detail
Nov 3, 2016 Acquired Acquired Cepheid (CIK 1037760). Its filings from before the deal are on its own company page, not shown here.
May 21, 2015 Acquired Acquired Pall Corp (CIK 75829). Its filings from before the deal are on its own company page, not shown here.
May 10, 2012 Acquired Acquired X Rite Inc (CIK 790818). Its filings from before the deal are on its own company page, not shown here.
May 10, 2011 Acquired Acquired Beckman Coulter Inc (CIK 840467). Its filings from before the deal are on its own company page, not shown here.
May 10, 2006 Acquired Acquired Sybron Dental Specialties Inc (CIK 1121302). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Danaher Corporation

ETF Weight in ETF Shares Market value As of
PRCS 5.74% 46,174 $ 10.23M Sep 30, 2026
BMED 5.19% 3,232 $ 743.069K Nov 16, 2026
EAGL 5.18% 1,158,537 $ 220.678M Jun 30, 2026
LRGG 4.33% 60,038 $ 11.436M Jun 30, 2026
CVRD 4.29% 7,200 $ 1.371M Jun 30, 2026
JXX 4.03% 5,508 $ 1.074M Jul 31, 2026
FMED 3.73% 9,000 $ 1.922M Aug 31, 2026
NPFE 3.57% 118,897 $ 23.183M Jul 31, 2026
BCHP 3.22% 36,941 $ 7.037M Jun 30, 2026
EQTY 3.22% 235,300 $ 45.879M Jul 31, 2026
AIVL 3.07% 67,025 $ 12.767M Jun 30, 2026
HRTS 2.98% 7,756 $ 1.656M Aug 31, 2026
TMED 2.96% 3,580 $ 681.918K Jun 30, 2026
JDOC 2.79% 1,223 $ 276.117K Nov 17, 2026
ASLV 2.62% 29,365 $ 5.726M Jul 31, 2026
BASG 2.56% 66,390 $ 12.646M Jun 30, 2026
GRW 1.92% 6,380 $ 1.244M Jul 31, 2026
THMZ 1.88% 5,346 $ 1.018M Jun 30, 2026
CGVV 1.74% 15,400 $ 3.541M Nov 16, 2026
BAFE 1.72% 152,974 $ 29.138M Jun 30, 2026
TCAL 1.45% 20,890 $ 4.803M Nov 17, 2026
TCAF 1.43% 667,895 $ 153.556M Nov 17, 2026
ROPE 1.34% 1,464 $ 330K Nov 18, 2026
MEDI 1.30% 2,524 $ 585.972K Nov 12, 2026
PSET 1.24% 1,868 $ 355.817K Jun 30, 2026
AGRW 1.10% 6,377 $ 1.243M Jul 31, 2026
TGLB 1.07% 1,437 $ 280.186K Jul 31, 2026
BKDV 1.03% 96,880 $ 18.89M Jul 31, 2026
CGCV 1.02% 108,904 $ 25.038M Nov 16, 2026
FPAG 0.99% 28,133 $ 5.359M Jun 30, 2026
SURE 0.99% 2,527 $ 570.521K Nov 17, 2026
CGGE 0.96% 136,133 $ 31.298M Nov 16, 2026
SPIN 0.96% 1,854 $ 426.253K Nov 16, 2026
JAVA 0.93% 307,255 $ 69.369M Nov 17, 2026
ACLC 0.85% 12,931 $ 2.762M Aug 31, 2026
MKTN short -0.79% -4,410 $ -840.017K Jun 30, 2026
LVDS 0.78% 4,150 $ 936.946K Nov 17, 2026
PRAY 0.77% 3,169 $ 603.631K Jun 30, 2026
MFSG 0.68% 12,090 $ 2.582M Aug 31, 2026
JSTC 0.66% 8,453 $ 1.943M Nov 17, 2026
PINK 0.61% 9,089 $ 2.052M Nov 17, 2026
FFLC 0.59% 36,489 $ 7.115M Jul 31, 2026
HELX 0.57% 842 $ 160.384K Jun 30, 2026
PAPI 0.56% 11,779 $ 2.244M Jun 30, 2026
ACVU 0.55% 6,771 $ 0.00 Nov 18, 2026
CAPE 0.55% 6,871 $ 1.309M Jun 30, 2026
TIME 0.54% 350 $ 80.469K Nov 17, 2026
FELV 0.49% 81,816 $ 15.584M Jun 30, 2026
BDYN 0.43% 56,218 $ 12.925M Nov 16, 2026
DFUV 0.41% 278,400 $ 64.633M Nov 12, 2026
MODL 0.36% 19,417 $ 3.699M Jun 30, 2026
XMAG 0.34% 3,165 $ 734.786K Nov 13, 2026
NBCR 0.34% 13,404 $ 2.863M Aug 31, 2026
FELC 0.32% 131,039 $ 24.96M Jun 30, 2026
GPT 0.31% 390 $ 74.287K Jun 30, 2026
WINN 0.30% 16,787 $ 3.912M Nov 13, 2026
INRO 0.29% 7,502 $ 1.725M Nov 16, 2026
LDRX 0.28% 3,379 $ 721.619K Aug 31, 2026
DFLV 0.28% 92,391 $ 21.449M Nov 12, 2026
TVAL 0.24% 12,072 $ 2.775M Nov 17, 2026
GSPY 0.24% 7,203 $ 1.656M Nov 17, 2026
ACVF 0.23% 1,783 $ 347.649K Jul 31, 2026
STOX 0.23% 2,383 $ 508.913K Aug 31, 2026
DFUS 0.21% 197,815 $ 45.925M Nov 12, 2026
SFTY 0.21% 7,839 $ 1.674M Aug 31, 2026
GDE 0.20% 4,449 $ 950.128K Aug 31, 2026
NTSD 0.20% 368 $ 70.097K Jun 30, 2026
TACU 0.19% 155 $ 35.636K Nov 17, 2026
VOXP 0.19% 57 $ 11.114K Jul 31, 2026
CGNG 0.19% 23,689 $ 5.446M Nov 16, 2026
ADME 0.19% 2,836 $ 552.963K Jul 31, 2026
ACIO 0.19% 22,752 $ 4.436M Jul 31, 2026
GEW 0.18% 1,245 $ 265.882K Aug 31, 2026
APUE 0.18% 20,690 $ 4.419M Aug 31, 2026
AAUS 0.17% 3,905 $ 880K Nov 18, 2026
DFSU 0.16% 16,876 $ 3.918M Nov 12, 2026
DFAU 0.16% 90,680 $ 21.052M Nov 12, 2026
NTSX 0.16% 11,606 $ 2.211M Jun 30, 2026
LGDX 0.16% 967 $ 222.323K Nov 17, 2026
HCMT 0.15% 4,381 $ 854.207K Jul 31, 2026
MSLC 0.15% 28,552 $ 6.098M Aug 31, 2026
VFVA 0.14% 6,376 $ 1.362M Aug 31, 2026
DCOR 0.14% 271,219 $ 62.966M Nov 12, 2026
THRO 0.11% 51,163 $ 11.763M Nov 16, 2026
DFAC 0.11% 411,150 $ 95.453M Nov 12, 2026
AVUS 0.10% 60,633 $ 13.94M Nov 16, 2026
AVSU 0.10% 2,104 $ 483.731K Nov 16, 2026
DYNF 0.10% 171,895 $ 39.52M Nov 16, 2026
AVLC 0.09% 6,432 $ 1.479M Nov 16, 2026
CSHP 0.08% 1,283 $ 294.975K Nov 16, 2026
FBCG 0.07% 25,158 $ 4.905M Jul 31, 2026
DAK 0.07% 125 $ 30K Nov 18, 2026
DXUV 0.05% 13,644 $ 3.168M Nov 12, 2026
IALT short -0.05% -15,806 $ -3.634M Nov 16, 2026
EBI 0.02% 627 $ 133.902K Aug 31, 2026
CORO 0.00% 395 $ 90.721K Nov 16, 2026
JUSA 0.00% 2 $ 451.54 Nov 17, 2026